Hoth therapeutics (hoth) and silo pharma (nasdaq: silo) today announced the formation of a 50/50 joint venture to develop a first-in-class gdnf-based therapy licensed from the u.s. department of veterans affairs. the therapy targets obesity and fatty liver disease.

*hoth therapeutics and silo pharma launch joint venture to commercialize va-invented obesity drug targeting $100b+ global market exclusive license from u.s. department of veterans affairs to advance gdnf-based therapy for obesity and fatty liver disease new york , june 25, 2025 /prnewswire/ -- hoth therapeutics, inc. (nasdaq: hoth) and silo pharma, inc. (nasdaq: silo) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the u.s. department of veterans affairs (va). the novel therapeutic platform centers on glial cell line-derived neurotrophic factor (gdnf), a va-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models.
SILO Ratings Summary
SILO Quant Ranking